Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14261646 | 1.00 | BTK (0.62) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL14261648 | 1.00 | BTK (0.62) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL14270420 | 1.00 | BTK (0.62) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL13337688 | 1.00 | BTK (0.62) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL14270414 | 1.00 | BTK (0.62) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL22334237 | 1.00 | BTK (0.62) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL573239 | 0.91 | BTK (0.55) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL573238 | 0.91 | BTK (0.55) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL5473239 | 0.91 | BTK (0.55) | BTKKDM1AMAOBCTSKCA1 | |
| SCHEMBL29366241 | 0.90 | BTK (0.77) | BTKKDM1AMAOBCTSKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151594-A1 | FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-110092726-B | Synthesis method of Bictegravir intermediate | 山东省医学科学院药物研究所（山东省抗衰老研究中心、山东省新技术制药研究所） | 2022-04-08 | — | — | CN | disclosed |
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| WO-2019144912-A1 | β-LACTAMASE INHIBITOR AND USE THEREOF | 苏州信诺维医药科技有限公司 | 2019-08-01 | — | — | WO | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | MERCK & CO., INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | MERCK & CO., INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | BTK 39/4885KDM1A 334/4885MAOB 2103/4885 |
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | BTK 3009/4885KDM1A 2951/4885MAOB 198/4885 |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | BTK 4766/4885KDM1A 1021/4885MAOB 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.